These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 9004172

  • 1. GH secretion in Prader-Labhard-Willi syndrome: somatotrope responsiveness to GHRH is enhanced by arginine but not by pyridostigmine.
    Beccaria L, Bosio L, Sanzari A, Aimaretti G, Ghigo E, Chiumello G.
    J Pediatr Endocrinol Metab; 1996; 9(6):577-83. PubMed ID: 9004172
    [Abstract] [Full Text] [Related]

  • 2. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 3. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [Abstract] [Full Text] [Related]

  • 4. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 5. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhard-Willi syndrome.
    Cappa M, Grossi A, Borrelli P, Ghigo E, Bellone J, Benedetti S, Carta D, Loche S.
    Horm Res; 1993 Oct; 39(1-2):51-5. PubMed ID: 8406340
    [Abstract] [Full Text] [Related]

  • 6. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 7. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M, Maccario M, Savio P, Valetto MR, Aimaretti G, Grottoli S, Oleandri SE, Baffoni C, Tassone F, Arvat E, Camanni F, Ghigo E.
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [Abstract] [Full Text] [Related]

  • 8. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.
    Corrias A, Bellone J, Beccaria L, Bosio L, Trifirò G, Livieri C, Ragusa L, Salvatoni A, Andreo M, Ciampalini P, Tonini G, Crinò A.
    J Endocrinol Invest; 2000 Feb; 23(2):84-9. PubMed ID: 10800760
    [Abstract] [Full Text] [Related]

  • 9. Arginine potentiates the GHRH- but not the pyridostigmine-induced GH secretion in normal short children. Further evidence for a somatostatin suppressing effect of arginine.
    Ghigo E, Bellone J, Mazza E, Imperiale E, Procopio M, Valente F, Lala R, De Sanctis C, Camanni F.
    Clin Endocrinol (Oxf); 1990 Jun; 32(6):763-7. PubMed ID: 1974484
    [Abstract] [Full Text] [Related]

  • 10. The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome.
    Arvat E, Gianotti L, Ragusa L, Valetto MR, Cappa M, Aimaretti G, Ramunni J, Grottoli S, Camanni F, Ghigo E.
    Dementia; 1996 Jun; 7(5):288-92. PubMed ID: 8872421
    [Abstract] [Full Text] [Related]

  • 11. Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome.
    Beccaria L, Benzi F, Sanzari A, Bosio L, Brambilla P, Chiumello G.
    J Endocrinol Invest; 1996 Nov; 19(10):687-92. PubMed ID: 9007701
    [Abstract] [Full Text] [Related]

  • 12. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M, Maccario M, Savio P, Valetto MR, Aimaretti G, Grottoli S, Oleandri SE, Baffoni C, Tassone F, Arvat E, Camanni F, Ghigo E.
    Minerva Endocrinol; 1999 Nov; 24(3-4):107-11. PubMed ID: 10953725
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children.
    Bellone J, Ghigo E, Procopio M, Arvat E, Valente F, Boffano GM, Maccario M, Dentelli P, Camanni F.
    Panminerva Med; 1993 Mar; 35(1):1-4. PubMed ID: 8316397
    [Abstract] [Full Text] [Related]

  • 14. Acute administration of recombinant human growth hormone inhibits the somatotrope responsiveness to growth hormone-releasing hormone in childhood.
    Bellone J, Aimaretti G, Valetto MR, Bellone S, Baffoni C, Arvat E, Seminara S, Camanni F, Ghigo E.
    Eur J Endocrinol; 1996 Oct; 135(4):421-4. PubMed ID: 8921823
    [Abstract] [Full Text] [Related]

  • 15. Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan.
    Valetto MR, Bellone J, Baffoni C, Savio P, Aimaretti G, Gianotti L, Arvat E, Camanni F, Ghigo E.
    Eur J Endocrinol; 1996 Nov; 135(5):568-72. PubMed ID: 8980159
    [Abstract] [Full Text] [Related]

  • 16. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, Imperiale E, Mazza E, Baracchi G, Camanni F.
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [Abstract] [Full Text] [Related]

  • 17. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome.
    Grugni G, Guzzaloni G, Moro D, Bettio D, De Medici C, Morabito F.
    Clin Endocrinol (Oxf); 1998 Jun; 48(6):769-75. PubMed ID: 9713567
    [Abstract] [Full Text] [Related]

  • 18. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G, Grugni G, Morabito F.
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [Abstract] [Full Text] [Related]

  • 20. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.